1310 related articles for article (PubMed ID: 8778032)
1. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
[TBL] [Abstract][Full Text] [Related]
2. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
3. The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells.
Okamoto T; Harada M; Shinomiya Y; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Mar; 40(3):173-81. PubMed ID: 7728776
[TBL] [Abstract][Full Text] [Related]
4. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
[TBL] [Abstract][Full Text] [Related]
5. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Liu J; Finke J; Krauss JC; Shu S; Plautz GE
Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455
[TBL] [Abstract][Full Text] [Related]
7. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
Li Q; Yu B; Grover AC; Zeng X; Chang AE
J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
10. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
12. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
13. Synergy between CD28 and CD9 costimulation for naive T-cell activation.
Toyo-oka K; Tai XG; Yashiro Y; Ahn HJ; Abe R; Hamaoka T; Kobayashi M; Neben S; Fujiwara H
Immunol Lett; 1997 Jun; 58(1):19-23. PubMed ID: 9436464
[TBL] [Abstract][Full Text] [Related]
14. Role of mRNA stability in the different patterns of cytokine production by CD4+ cells from young and old mice.
Pioli C; Pucci S; Barile S; Frasca D; Doria G
Immunology; 1998 Jul; 94(3):380-7. PubMed ID: 9767421
[TBL] [Abstract][Full Text] [Related]
15. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
Krauss JC; Strome SE; Chang AE; Shu S
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
[TBL] [Abstract][Full Text] [Related]
17. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial.
Lum LG; LeFever AV; Treisman JS; Garlie NK; Hanson JP
J Immunother; 2001; 24(5):408-19. PubMed ID: 11696696
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
Tanaka H; Tanaka J; Kjaergaard J; Shu S
J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
[TBL] [Abstract][Full Text] [Related]
20. Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential.
Okamoto T; Harada M; Tamada K; Yoshida H; Ito O; Kong YY; Takenoyama M; Hirashima C; Matsuzaki G; Nomoto K
Int J Cancer; 1997 Mar; 70(5):598-605. PubMed ID: 9052762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
